Daina Graybosch
Stock Analyst at Leerink Partners
(0.85)
# 3,952
Out of 5,032 analysts
104
Total ratings
37.84%
Success rate
-10.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Initiates: Outperform | $9 | $5.77 | +55.98% | 1 | Oct 3, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $2.17 | -7.83% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.74 | +169.11% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.80 | +288.89% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $20.99 | -42.83% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $84.79 | +40.35% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.48 | +35.14% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.75 | +247.78% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $86.95 | -55.15% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $57.77 | -22.10% | 10 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $14 | $0.54 | +2,481.60% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $1.47 | +580.27% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $16.47 | +130.72% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.92 | +104.09% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $105.14 | +113.05% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.30 | +1,204.35% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.60 | +962.50% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.88 | +380.00% | 4 | Feb 25, 2022 |
I-Mab
Oct 3, 2025
Initiates: Outperform
Price Target: $9
Current: $5.77
Upside: +55.98%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $2.17
Upside: -7.83%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.74
Upside: +169.11%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.80
Upside: +288.89%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $20.99
Upside: -42.83%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $84.79
Upside: +40.35%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.48
Upside: +35.14%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.75
Upside: +247.78%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $86.95
Upside: -55.15%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $57.77
Upside: -22.10%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.54
Upside: +2,481.60%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.47
Upside: +580.27%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $16.47
Upside: +130.72%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.92
Upside: +104.09%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $105.14
Upside: +113.05%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.30
Upside: +1,204.35%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.60
Upside: +962.50%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.88
Upside: +380.00%